<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7101493\results\search\disease\results.xml">
  <result pre="Viewpoints Leaving no one behind: Towards equitable global elimination of" exact="hepatitis C" post="DahlElin Hoffmann12ZahidHassaan3AslamKhawar3JafriWasim4[1], [2], [3], [4], Correspondence to: Dr. Elin Hoffmann"/>
  <result pre="International License. fig-count: table-count: equation-count: ref-count: page-count: Until the 1950s," exact="tuberculosis" post="(TB) was a public health threat in many high-income"/>
  <result pre="health problemâ€� by 2050 [2] â€&quot; a century after the" exact="disease" post="came under control in high income countries. Today, the"/>
  <result pre="totally drug resistant (XDR-TB) are adding to the complexity of" exact="disease" post="control; limited funds, that could once have gone directly"/>
  <result pre="resistant (XDR-TB) are adding to the complexity of disease control;" exact="limited" post="funds, that could once have gone directly into public"/>
  <result pre="to tackle drug-resistant disease. This provides a cautionary tale for" exact="hepatitis C" post="elimination. At the discovery of the â€œnon-A, non-B hepatitisâ€�"/>
  <result pre="of the â€œnon-A, non-B hepatitisâ€� virus in 1989, later named" exact="hepatitis C" post="(HCV), this disease was unknown and untreatable, and many"/>
  <result pre="hepatitisâ€� virus in 1989, later named hepatitis C (HCV), this" exact="disease" post="was unknown and untreatable, and many naturally considered the"/>
  <result pre="prolonged course of injected therapy with extensive side-effects, and ineffective" exact="viral" post="clearance with frequent relapse. Treatment was revolutionized in 2011"/>
  <result pre="which have vastly shorter treatment courses and virtually no side-effects." exact="Viral" post="clearance increased from around 50% with injected interferon to"/>
  <result pre="This development has been a pivotal in the control of" exact="hepatitis C." post="In many countries with well-functioning health services, HCV is"/>
  <result pre="In many countries with well-functioning health services, HCV is already" exact="limited" post="to subgroups of the population. Countries such as the"/>
  <result pre="In Pakistan, the country with the second largest burden of" exact="hepatitis C," post="prevalence data from recent years has shown around a"/>
  <result pre="good intentions with the necessary financial commitment to eliminate the" exact="disease" post="[5]. The global resurgence in HCV control has been"/>
  <result pre="prices, which rich and poor nations alike struggled to afford." exact="Hepatitis" post="C has, for a brief period in time, been"/>
  <result pre="â€œeveryoneâ€™s problemâ€�. In a few years HCV could be another" exact="disease" post="of the poor, restricted to low and middle-income countries"/>
  <result pre="but a lack of knowledge: 90% of people living with" exact="viral hepatitis" post="are unaware of their status. In high prevalence settings"/>
  <result pre="a lack of knowledge: 90% of people living with viral" exact="hepatitis" post="are unaware of their status. In high prevalence settings"/>
  <result pre="testing, and the validation of low-cost approaches to the assessment" exact="of liver" post="status (ie, APRI score). Furthermore, clinical trials have shown"/>
  <result pre="be treated within the same service capacity. Currently, confirmation of" exact="viral" post="clearance following treatment is recommended for all patients. With"/>
  <result pre="been done for TB. We believe that as with other" exact="infectious diseases" post="focus must be put on contact-tracing with the implementation"/>
  <result pre="barbers and hygiene products. This is an established concept within" exact="infectious disease" post="approaches to preventing re-infections and missed opportunities within communities"/>
  <result pre="and hygiene products. This is an established concept within infectious" exact="disease" post="approaches to preventing re-infections and missed opportunities within communities"/>
  <result pre="in years to come. Few predicted the rapid rise of" exact="MDR-TB" post="when multiple drug-regimens were made available 60 years ago,"/>
  <result pre="available 60 years ago, nor the evolution of XDR-TB. If" exact="hepatitis C" post="becomes a disease of the poor as was once"/>
  <result pre="nor the evolution of XDR-TB. If hepatitis C becomes a" exact="disease" post="of the poor as was once the case of"/>
  <result pre="and progress can be lost. Prevention must remain at the" exact="heart" post="of tackling the HCV epidemic. Lifting people out of"/>
  <result pre="Lifting people out of poverty and eliminating the spread of" exact="disease" post="though health services, including local practitioners, is therefore key"/>
  <result pre="programs, including strong financial commitment. Treatment of all patients with" exact="chronic" post="HCV has been shown to not only be cost-effective,"/>
  <result pre="long run as an earlier intervention prevents the development of" exact="cirrhosis" post="[9]. Others can learn from Egypt, the country with"/>
  <result pre="learn from Egypt, the country with the world's largest HCV" exact="disease" post="burden. The problem has been a high priority for"/>
  <result pre="goals through driving down drug prices, optimizing procurement processes, improving" exact="infection" post="control and blood safety, introducing mass education programs, improving"/>
  <result pre="recognize the risk of history repeating itself and not allow" exact="hepatitis C" post="to follow the same path as TB. With incidence"/>
  <result pre="necessary financial commitments, to meet the WHO goal of eliminating" exact="hepatitis C" post="as a public health threat globally by 2030. Acknowledgements"/>
  <result pre="thank all the staff at the MÃ©decins Sans FrontiÃ¨res (MSF)" exact="Hepatitis" post="C clinic, Karachi, for their dedication and hard work"/>
  <result pre="their dedication and hard work to reduce the burden of" exact="hepatitis C." post="Funding: None. Authorship contributions: EHD and HZ conceived the"/>
  <result pre="conflicts of interest. References REFERENCES 1Norwegian Institute of Public Health." exact="Tuberculosis" post="(TB) in Norway - fact sheet. Available: https://www.fhi.no/en/id/infectious-diseases/TB/tuberculosis-tb-in-norwayâ€&quot;fact-sh/. Accessed:"/>
  <result pre="3Foundation CDA. Just 12 countries worldwide on track to eliminate" exact="hepatitis C" post="infection by 2030. http://cdafound.org/just-12-countries-worldwide-on-track-to-eliminate-hepatitis-c-infection-by-2030-with-united-kingdom-italy-and-spain-among-those-joining-the-list/. Accessed: 20 November 2019. 4JafriWSiddiquiBAwanSHCV-"/>
  <result pre="Just 12 countries worldwide on track to eliminate hepatitis C" exact="infection" post="by 2030. http://cdafound.org/just-12-countries-worldwide-on-track-to-eliminate-hepatitis-c-infection-by-2030-with-united-kingdom-italy-and-spain-among-those-joining-the-list/. Accessed: 20 November 2019. 4JafriWSiddiquiBAwanSHCV- discovery"/>
  <result pre="20 November 2019. 4JafriWSiddiquiBAwanSHCV- discovery to elimination, â€œmyth or reality." exact="Hepatoma" post="Res. 2018;4:5410.20517/2394-5079.2018.36 5WHO. Progress Report on Access to Hepatitis"/>
  <result pre="reality. Hepatoma Res. 2018;4:5410.20517/2394-5079.2018.36 5WHO. Progress Report on Access to" exact="Hepatitis" post="C Treatment. Available: http://apps.who.int/iris/bitstream/handle/10665/260445/WHO-CDS-HIV-18.4-eng.pdf;jsessionid=19538832780C2D8B7DB87B6B17B25C19?sequence=1. Accessed: 20 November 2019. 6Hill"/>
  <result pre="Available: http://apps.who.int/iris/bitstream/handle/10665/260445/WHO-CDS-HIV-18.4-eng.pdf;jsessionid=19538832780C2D8B7DB87B6B17B25C19?sequence=1. Accessed: 20 November 2019. 6Hill A. Access to" exact="hepatitis" post="medicines. World Hepatitis Summit 2017. Available: http://www.worldhepatitissummit.org/docs/default-source/presentations/strategic-direction-2/access-to-hepatitis-medicines-(andrew-hill).pdf?sfvrsn=2. Accessed: 16"/>
  <result pre="20 November 2019. 6Hill A. Access to hepatitis medicines. World" exact="Hepatitis" post="Summit 2017. Available: http://www.worldhepatitissummit.org/docs/default-source/presentations/strategic-direction-2/access-to-hepatitis-medicines-(andrew-hill).pdf?sfvrsn=2. Accessed: 16 December 2019. 7KattakuzhySGrossCEmmanuelBTeferiGJenkinsVSilkRet"/>
  <result pre="http://www.worldhepatitissummit.org/docs/default-source/presentations/strategic-direction-2/access-to-hepatitis-medicines-(andrew-hill).pdf?sfvrsn=2. Accessed: 16 December 2019. 7KattakuzhySGrossCEmmanuelBTeferiGJenkinsVSilkRet al.Expansion of treatment for" exact="Hepatitis" post="C Virus infection by task shifting to community-based nonspecialist"/>
  <result pre="December 2019. 7KattakuzhySGrossCEmmanuelBTeferiGJenkinsVSilkRet al.Expansion of treatment for Hepatitis C Virus" exact="infection" post="by task shifting to community-based nonspecialist providers: A nonrandomized"/>
  <result pre="Gastroenterol Hepatol. 2018;3:819. 10.1016/S2468-1253(18)30281-430507463 10EsmatGEl-SayedMHHassanyMDossWWakedIOne step closer to elimination of" exact="hepatitis C" post="in Egypt.Lancet Gastroenterol Hepatol. 2018;3:665. 10.1016/S2468-1253(18)30268-130215356"/>
 </snippets>
</snippetsTree>
